Feasibility of recruitment to an oral dysplasia trial in the United Kingdom

Head and Neck Oncology

Volumn 4, Issue 1, 2012, Pages

  Nankivell, Paul ^a,b   Dunn, Janet ^c   Langman, Michael ^d   Mehanna, Hisham ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Aspirin; Clinical trial; Feasibility; Oral dysplasia

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HYPERSENSITIVITY; DYSPLASIA; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; INCIDENCE; LEUKOPLAKIA; MOUTH MALFORMATION; MULTICENTER STUDY; ORAL BIOPSY; ORAL EPITHELIAL DYSPLASIA; PRIORITY JOURNAL; UNITED KINGDOM;

ASPIRIN; CLINICAL TRIALS, PHASE I AS TOPIC; FEASIBILITY STUDIES; GREAT BRITAIN; HUMANS; LEUKOPLAKIA, ORAL; PATIENT SELECTION;

EID: 84862604123     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-4-40     Document Type: Article

References (32)

1. Nomenclature and classification of potentially malignant disorders of the oral mucosa. Warnakulasuriya S, Johnson NW, der Waal van I, J Oral Pathol Med 2007 36 10 575 580 10.1111/j.1600-0714.2007.00582.x 17944749
2. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35years. Bouquot JE, Gorlin RJ, Oral Surg Oral Med Oral Pathol 1986 61 373 381 10.1016/0030-4220(86)90422-6 3458148
3. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Waldron CA, Shafer WG, Cancer 1975 36 1386 1392 10.1002/1097-0142(197510)36: 4<1386::AID-CNCR2820360430>3.0.CO;2-7 1175136
4. Carcinoma and dysplasia in oral leukoplakias in Taiwan: prevalence and risk factors. Lee J-J, Hung H-C, Cheng S-J, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006 101 472 480 10.1016/j.tripleo.2005.07.024 16545712
5. Oral leukoplakia-rationale for diagnosis and prognosis of its clinical subtypes or "phases". Bouquot JE, Whitaker SB, Quintessence Int 1994 25 133 140 8183979
6. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. Hsue SS, Wang WC, Chen CH, et al. J Oral Pathol Med 2007 36 25 29 17181738
7. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Silverman SJ, Gorsky M, Lozada F, Cancer 1984 53 563 568 10.1002/1097-0142(19840201)53:3<563::AID-CNCR2820530332>3.0.CO;2-F 6537892
8. Treatment and follow-up of oral dysplasia-a systematic review and meta-analysis. Mehanna HM, Rattay T, Smith J, et al. Head Neck 2009 31 1600 1609 10.1002/hed.21131 19455705
9. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Siegel R, Ward E, Brawley O, et al. CA Cancer J Clin 2011 61 212 236 10.3322/caac.20121 21685461
10. Oral Dysplasia: Biomarkers, Treatment, and Follow-up. Nankivell P, Mehanna H, Curr Oncol Rep 2011 13 145 152 10.1007/s11912-010-0150-z 21249481
11. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Der Waal Van I, Oral Oncol 2010 46 423 425 10.1016/j.oraloncology.2010.02.016 20308005
12. Interventions for treating oral leukoplakia. Lodi G, Sardella A, Bez C, et al. Cochrane Database Syst Rev 2006 18 D001829
13. Outcome of oral dysplasia: a retrospective hospital-based study of 207 patients with a long follow-up. Arduino PG, Surace A, Carbone M, et al. J Oral Pathol Med 2009 38 540 544 10.1111/j.1600-0714.2009.00782.x 19453839
14. The results of CO2 laser surgery in patients with oral leukoplakia: a 25year follow up. van der Hem PS, Nauta JM, van der Wal JE, et al. Oral Oncol 2005 41 31 37 10.1016/j.oraloncology.2004.06.010 15598583
15. Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas. Zhang S, Du Y, Tao J, et al. ORL J Otorhinolaryngol Relat Spec 2008 70 242 248 10.1159/000130872 18467819
16. Cyclo-oxygenase-1 and 2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Shibata M, Kodani I, Osaki M, et al. Oral Oncol 2005 41 304 312 10.1016/j.oraloncology.2004.09.009 15743693
17. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Nathan CA, Leskov IL, Lin M, et al. Cancer 2001 92 1888 1895 10.1002/1097-0142(20011001)92:7<1888::AID-CNCR1706>3.0.CO;2-Z 11745262
18. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Shaheen NJ, Straus WL, Sandler RS, Cancer 2002 94 950 963 10.1002/cncr.10333 11920463
19. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Wirth LJ, Krane JF, Li Y, et al. Cancer Prev Res (Phila) 2008 1 339 348 10.1158/1940-6207.CAPR-07-0003
20. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Papadimitrakopoulou VA, William WN, Dannenberg AJ, et al. Clin Cancer Res 2008 14 2095 2101 10.1158/1078-0432.CCR-07-4024 18381950
21. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Mulshine JL, Atkinson JC, Greer RO, et al. Clin Cancer Res 2004 10 1565 1573 10.1158/1078-0432.CCR-1020-3 15014005
22. Trends in the relative frequency of histologically diagnosed epithelial dysplasia and intra-oral carcinoma in Northern Ireland, 1975-1989. Gregg TA, Cowan CG, Kee F, Br Dent J 1992 173 234 236 10.1038/sj.bdj.4808006 1298233
23. Oral epithelial dysplasia: clinical characteristics of western European residents. Jaber MA, Porter SR, Speight P, et al. Oral Oncol 2003 39 589 596 10.1016/S1368-8375(03)00045-9 12798402
24. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. Napier SS, Speight PM, J Oral Pathol Med 2008 37 1 10 18154571
25. A follow up study of oral cancer and precancerous lesions in 57,518 industrial workers of Gujarat, India. Bhargava K, Smith LW, Mani NJ, et al. Indian J Canc 1975 12 124 129
26. Oral leukoplakia in relation to tobacco habits. A ten-year follow-up study of Bombay policemen. Mehta FS, Shroff BC, Gupta PC, et al. Oral Surg Oral Med Oral Pathol 1972 34 426 433 10.1016/0030-4220(72)90319-2 4505755
27. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. Mehta FS, Pindborg JJ, Gupta PC, et al. Cancer 1969 24 832 849 10.1002/1097-0142(196910)24:4<832::AID-CNCR2820240427>3.0.CO;2- U 4898206
28. Occurrence of leukoplakia and some other oral white lesions among 20,333 adult Swedish people. Axéll T, Commun Dent Oral Epidemiol 1987 15 46 51 10.1111/j.1600-0528.1987.tb00479.x
29. Prevalence study of oral leukoplakia in a selected population of 1000 patients from The Netherlands. Hogewind WF, der Waal van I, Commun Dent Oral Epidemiol 1988 16 302 305 10.1111/j.1600-0528.1988.tb01781.x
30. Opportunistic screening for oral cancer and precancer in general dental practice: results of a demonstration study. Lim K, Moles DR, Downer MC, et al. Br Dent J 2003 194 497 502 discussion493 10.1038/sj.bdj.4810069 12835785
31. Pooled estimate of world leukoplakia prevalence: a systematic review. Petti S, Oral Oncol 2003 39 770 780 10.1016/S1368-8375(03)00102-7 13679200
32. Case-control study of oral dysplasia and risk habits among patients of a dental hospital. Kulasegaram R, Downer MC, Jullien JA, et al. Eur J Cancer B Oral Oncol 1995 31B 227 231 7492917